Investor Presentaiton
FY 2020 Key operational highlights
Strong performance and resilience of our core business, despite the impact of multiple lockdowns around the world
•
Great collaboration across borders and business lines:
。 Exceptionally quick ramp-up in response to the COVID-19 pandemic crisis
。 Significant contribution to public health authorities' fight against the pandemic, helping ensure uninterrupted access
to safe food, water, medicines, essential products and services to the public
Innovative product launches:
。 SAFER@WORKTM Programmes for employer, environmental surface, site wastewater and product testing
。 COVID-19 RT-PCR tests with easy and reliable at-home self-sampling options
。 GSD NovatypeⓇ RT-PCR for fast variant identification
。 GSD NovaPrimeⓇ SARS-CoV-2, successfully validated for pharynx gargle and saliva samples
。 CE-IVD marked rapid point-of-care finger-prick testing devices to identify past exposure to COVID-19
。 Large Next Generation Sequencing (NGS) capacity and PCR/NGS Primer sets to detect Variants
Completing our significant investment programme:
。 Integration of prior acquisitions and finalisation of hub and spoke laboratory network
Becoming fully digital
o Limited M&A activity
eurofins
6View entire presentation